“The 2026 advisory vote added DSIP to the 503A list or approved it.”

01 · Answer

Misleading

The July 2026 committee vote was advisory. It did not itself change the 503A list or approve a drug. The current U.S. list does not show DSIP or emideltide, and no final FDA approval was identified in this review.

What kind of evidence this is

Regulatory or product record. This answer uses an official regulator record or a specific product label.

What this answer covers

The July 2026 advisory vote and United States 503A status as reviewed August 30, 2026; an advisory recommendation is not a final FDA decision or drug approval. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.

Question type

Approval and status. Whether a specific product has an approval or another official status.